The American Cancer Society updated colorectal cancer screening guidelines to incorporate additional noninvasive tests, including new blood-based and at-home stool options. The guidance, published in CA: A Cancer Journal for Clinicians, highlights eligibility considerations for tests offered by Guardant Health, Freenome, Geneoscopy, and Abbott. The update includes Guardant’s blood-based Shield and Freenome’s SimpleScreen, alongside Geneoscopy’s stool-based ColoSense assay and Abbott’s Cologuard Plus. It also reflects an emphasis on making screening more accessible outside colonoscopy, while continuing to specify appropriate use cases for different test modalities. For biotech and diagnostics stakeholders, the new guideline landscape directly affects utilization expectations and commercial planning for companies positioned in CRC testing.